TEL AVIV, Israel, Aug. 01, 2018 (GLOBE NEWSWIRE) -- VBL Therapeutics VBLT, a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announced that it will host a conference call and live audio webcast on Thursday, August 16 at 8:30am Eastern Time to report second quarter ended June 30, 2018 financial results.
Thursday, August 16th @ 8:30am Eastern Time | |
US Domestic: | 877-222-6394 |
International: | 703-925-2702 |
Conference ID: | 3572709 |
Webcast: | https://edge.media-server.com/m6/p/9dz8zzo9 |
Replays, Available through August 30, 2018 | |
US Domestic: | 855-859-2056 |
International: | 404-537-3406 |
Conference ID: | 3572709 |
About VBL
Vascular Biogenics Ltd., operating as VBL Therapeutics, is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class treatments for cancer. The Company's lead oncology product candidate, ofranergene obadenovec (VB-111), is a first-in-class, targeted anti-cancer gene-therapy agent that is positioned to treat a wide range of solid tumors. It is conveniently administered as an IV infusion once every two months. It has been observed to be well-tolerated in >300 cancer patients and demonstrated efficacy signals in an "all comers" Phase 1 trial as well as in three tumor-specific Phase 2 studies. Ofranergene obadenovec is currently being studied in a Phase 3 trial for platinum-resistant ovarian cancer.
INVESTOR CONTACT:
Michael Rice
LifeSci Advisors
mrice@lifesciadvisors.com
(646) 597-6979
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.